Join the Lymphoma group to help and get support from people like you.
Lymphoma News
Related terms: Cancer, Lymphoma
Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care
THURSDAY, Sept. 12, 2024 – The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy, according to a study...
Toxicities Rare After Two Weeks of CAR T-Cell Therapy Infusion
TUESDAY, July 30, 2024 – New-onset cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are rare beyond two weeks following infusion of CD19-directed...
Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma
WEDNESDAY, June 26, 2024 – Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL),...
New Hope for People With Aggressive Form of Lymphoma
FRIDAY, June 21, 2024 – An experimental cancer treatment regimen is achieving full remissions in some patients with aggressive B-cell lymphoma, researchers report. The five-drug combination does ...
ViPOR Results in Durable Remission in Specific Subtypes of Lymphoma
THURSDAY, June 20, 2024 – For patients with specific subtypes of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), treatment with venetoclax, ibrutinib, prednisone, obinutuzumab, and...
Second Tumors Are Rare After Chimeric Antigen Receptor T-Cell Therapy
FRIDAY, June 14, 2024 – Second tumors are rarely seen after chimeric antigen receptor (CAR) T-cell therapy, according to a study published in the June 13 issue of the New England Journal of...
Secondary Tumors After CAR-T Cancer Therapies Are Rare: Study
THURSDAY, June 13, 2024 – CAR-T cell therapy to treat blood cancers is safer than previously thought, with little risk that the immunotherapy will create secondary cancers, a new study finds. The...
Could Tattoos Be Linked to Blood Cancer Risk?
WEDNESDAY, May 29, 2024 – Research suggests that tattoo ink spurs inflammatory changes that might contribute to the development of lymphoma. The findings are early, however, and more study must be...
Tattoos May Increase Risk of Malignant Lymphoma
WEDNESDAY, May 29, 2024 – Tattoo exposure is associated with an increased risk of several malignant lymphoma subtypes, according to a study published online in the June issue of eClinicalMedicine. ...
Strategy with Cyclophosphamide Could Expand Stem Cell Donor Pool for People Battling Blood Cancers
TUESDAY, May 28, 2024 – An older drug used in a new way could open the path for more patients with potentially deadly blood cancers to receive a lifesaving stem cell transplant, a new study finds....
Lymphoma: Know Your Treatment Options
THURSDAY, May 16, 2024 – For anyone newly diagnosed with blood cancers known as lymphomas, their first question might be: What treatments can help? Of course, there have been big advances in...
CD7 CAR T-Cell Therapy, Stem-Cell Transplant Beneficial for CD7-Positive Tumors
THURSDAY, April 25, 2024 – For patients with relapsed or refractory CD7-positive leukemia or lymphoma, sequential CD7 chimeric antigen receptor (CAR) T-cell therapy followed by haploidentical...
Survival 21 Percent a Year After ICU Discharge for Blood Cancer Patients
THURSDAY, March 21, 2024 – For hematologic malignancy (HM) patients admitted to the intensive care unit (ICU), survival is 49 percent at seven days and 21 percent at 12 months, according to a study...
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma, Breyanzi
MONDAY, March 18, 2024 – The U.S. Food and Drug Administration has approved Breyanzi (lisocabtagene maraleucel [liso-cel]) as the first CD19-directed chimeric antigen receptor (CAR) T-cell therapy...
Risk Stratification Can Predict Outcomes for CAR T-Cell Therapy in Lymphoma
THURSDAY, Feb. 15, 2024 – For patients with diffuse large B-cell lymphoma (DLBCL), a simple risk stratification can predict outcomes for patients treated with CD19 chimeric antigen receptor (CAR)...
Further information
Related condition support groups
Non-Hodgkin's Lymphoma, Blood Disorders